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Chemotherapy  treats  many  types  of cancer  effectively  but  it often  causes  side  effects.
Chemotherapy  works  on active  cells,  such  as  cancer  cells,  and  some  healthy  cells.  Side
effects  happen  when  chemotherapy  damages  these  healthy  cells.  Today,  many  more
drugs  are  available  to treat  side  effects  than  in the  past. Triptorelin  (Decapeptyl)  is a
gonadotropin-releasing  hormone  agonist  that is reported  to  have  many  therapeutic  effects
besides being  an  anti-cancer  agent.  In the  current  study,  intraperitoneal  cyclophosphamide
(65  mg/kg/day)  was  administered  for 4 weeks  to induce  marked  dystrophic  changes  in
the  cerebral  cortex  and  hippocampus  of  male  albino  rats. After  4  weeks,  we  observed
signiﬁcant  degeneration  of neurocytes  with dystrophic  changes.  Subcutaneous  triptorelin
(0.05 mg/kg/day)  for  4 weeks  signiﬁcantly  improved  histological  signs  of degeneration  and
apoptosis.  Anti-Bcl2  staining  of sections  of  the  cerebral  cortex  and  hippocampus  showed
that the apoptotic  index  was increased.  This ﬁnding  was  conﬁrmed  by  the anti-p53  staining,
which  showed  a signiﬁcant  decrease  in  the  apoptotic  index.  Ultimately,  such  improve-
ments  were  accompanied  by  signiﬁcant  restoration  of  normal  brain  histology,  as  revealed
by  hematoxylin  and  eosin.  In  conclusion,  triptorelin  can  reverse  the  apoptotic  changes
induced  by cyclophosphamide  therapy,  which  is  more  marked  in the  hippocampus  than
cerebral  cortex.
di  Socie©  2015  Sau
. IntroductionManagement of many cancers has been achieved by
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chemotherapy is not speciﬁc, and places normal and can-
cer cells at risk by direct and/or indirect mechanisms [1].
Cancer patients can experience various adverse neurolog-
ical symptoms, including cognitive dysfunction. Several
studies reported that this was a real side effect of the dis-
ease and its treatment with chemotherapy on the brain
function [2,3]. Many studies have focused on the acute
effects of chemotherapy on cerebral cortex and hippocam-
pal function and have reported transient acute memory
ghts reserved.
scopy an124 H.S. Shaibah et al. / Journal of Micro
impairment in mice treated with a single dose of cyclophos-
phamide (CP) [4–6]. Recent radiological studies reported
that chemotherapy can induce partially reversible patho-
logical changes in the gray and white matter of the cerebral
cortex [7]. The hippocampus is one of the rare areas of
the brain that exhibits neurogenesis. These new neurons
created by the hippocampus are important for mem-
ory and learning and require brain-derived neurotrophic
factor (BDNF). Many chemotherapeutic agents, such as 5-
ﬂuorouracil, signiﬁcantly reduce the levels of BDNF in the
hippocampus of rats [8]. Other chemotherapeutic agents,
such as methotrexate, decrease hippocampal cell prolifer-
ation in rats following single intravenous injection [9].
CP is a cytotoxic alkylating agent that is most commonly
used as an anti-cancer agent [10]. Recent reports reveal that
intraperitoneal administration of CP causes oxidative stress
in the brain [11] and massive cellular damage [12], conse-
quently triggering apoptosis [13], and death of cancer and
healthy cells [14]. CP uptake into healthy cells is higher than
in cancer cells, rendering healthy cells more susceptible to
damage [15]. The antineoplastic effects of CP are associated
with phosphoramide mustard, while acrolein is linked with
its toxic side effects [16,17]. Acrolein interferes with the
tissue antioxidant defense system [18]. These metabolites
reduce cellular resistance to oxidative stress, which can
damage the blood–brain barrier [19]. CP can alkylate DNA,
which prevents the duplication of the genome in divid-
ing cells, arrests the S-phase of the cell cycle, and induces
apoptosis in embryonic neural progenitor cells of the tele-
ncephalon 6–12 hours after administration [20,21].
Cancer patients are not the only group who are exposed
to the hazards of CP. Pharmacists and nurses are also occu-
pationally exposed to the drug during its production or
distribution [22]. Dividing cells are sensitive to the cyto-
toxic effects of alkylating agents. It has been suggested that
inhibition of the pituitary–gonadal axis reduces the rate of
spermatogenesis as well as oogenesis [23].
Some immunoreactive studies have reported that
gonadotropin releasing hormone (GnRH) receptors were
detected in tissues taken from the cerebral cortex and
hippocampus, especially the cornu ammonis) [24]. GnRH
affects neuronal activity throughout the brain [25,26]. Trip-
torelin (Decapeptyl) is a GnRH agonist. It is used in the
treatment of hormone-responsive cancers, such as prostate
or breast cancer [27].
Bcl-2 is an antiapoptotic protein that suppress apopto-
sis. It is localized mainly in the mitochondrial membrane
and plays an important role in protecting tissues from
apoptotic cell death [28].
p53 is a tumor suppressor protein that plays a central
role in cell cycle arrest and apoptosis [29]. p53 is a proapo-
ptotic short-lived protein (half-life 10–30 minutes) that is
constitutively expressed at low levels in most cell types
including neurons [30].
2. Materials and Methods2.1. Animals
Forty male Sprague–Dawley rats (aged 8 weeks,
weight 200–250 g) were purchased from the Urologyd Ultrastructure 4 (2016) 123–132
and Nephrology Center, Experimental Animal Center,
Mansoura, Egypt. The rats were housed in cages at room
temperature (22–25 ◦C) and in a photoperiod of 14 hours
light/10 hours dark. The rats were housed in standard
animal facility under controlled environmental conditions
at room temperature 22±2 ◦C and a 12-hour light–dark
cycle and allowed access to food and water ad libitum.
All experiments were performed in line with the ethical
recommendations of the Faculty of Medicine, Mansoura
University, Egypt.
2.2. Experimental protocol
Rats were randomly divided into four groups of 10.
Group I: healthy normal control group that received
0.5 mL  saline by injection for 4 weeks; Group II: CP con-
trol that received intraperitoneal CP (Baxter Oncology,
USA, 65 mg/kg/day) for 4 weeks; Group III: triptorelin
(Decapeptyl, 1 mg)  control that received subcutaneous
triptorelin (Ferring, Switzerland, 0.05 mg/kg/day) for 4
weeks; and Group IV: triptorelin-treated group that
received intraperitoneal CP (65 mg/kg/day) and subcuta-
neous triptorelin (0.05 mg/kg/day) for 4 weeks. The rats
were anesthetized by inhalation of pentobarbital over-
dose (200 mg/kg) followed by rapid cervical dislocation and
decapitation. This was followed by harvesting of brain tis-
sues, which were placed in 10% formaldehyde.
2.3. Histopathology and immunohistochemical analysis
of anti-p53 and anti-Bcl-2 expression
The brains were cut coronally with a microtome (Leica
RM 2025; Nassloch, Germany) at 5 m thickness. Sec-
tions were ﬁxed in 10% buffered formalin and embedded
in parafﬁn. Three sets of slides were prepared. At least
two  different sections were examined per brain sam-
ple (cerebral cortex and hippocampus). The ﬁrst set was
stained with hematoxylin and eosin to assess histopatho-
logical changes [31]. The second set was  stained with
immunoperoxidase for evaluation of anti-p53 expression
in the nuclei (brown), which indicated positive apoptotic
neurocytes. The third set was stained for evaluation of
anti-Bcl-2 in the perinuclear membrane (brown), which
indicated positive nonapoptotic neurocytes [32]. Scoring
of immunohistochemically-stained neurocytes was done
under light microscopy and away from lesions. Semi-
quantiﬁcation analysis of the apoptotic index (AI) was
determined by counting at least 1000 cells per slide,
subdivided into 10 ﬁelds chosen randomly, at 400× mag-
niﬁcation. AI% = (number of positive cells/total number of
calculated cells) × 100, which represented the percentage
of positive cells in 1000 cells [33].
2.4. Statistical analysis
All data are presented as mean ± standard error of the
mean. All analyses were carried out using SPSS version
17. We  used one-way analysis of variance for comparison
between the means of the four groups, and the least signif-
icant difference test for comparison of each two individual
means. A value of p ≤ 0.05 was  considered statistically
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Figure 1. Photomicrograph of the cerebral cortex of a cyclophosphamide-
treated rat (Group II) showing neurons with dystrophic changes in the
form of shrunken hyperchromatic, irregular with chromatolysis and
abnormal Nissl granule distribution (arrows), with dilated blood vessel (*),
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Figure 2. Photomicrograph of an anti-Bcl2-stained section of the cere-
bral cortex of a cyclophosphamide-treated rat (Group II) showing
brown immunoreactive staining of perinuclear membranes of neuro-
cytes. Low immunoreactivity of apoptotic cells in cerebral cortex of
a  cyclophosphamide-treated rat (arrows). Stain: immunohistochemical
reaction for anti-p53 (Figures 12, 19 and 20; Table 1).nd  degenerate and vacuolated neurocytes (arrow heads). Stain: hema-
oxylin and eosin; magniﬁcation: 400×.
igniﬁcant. An independent sample t test was used post
oc to compare the four groups that were not paired. A
alue of p ≤ 0.001 was considered statistically signiﬁcant.
. Results
.1. Cyclophosphamide treated rats (Group II)
Light microscopic examination of the cerebral cortex of
P-treated rats showed degenerated and vacuolated neu-
ocytes with dystrophic changes in the form of shrunken,
yknotic and hyperchromatic nuclei (Figure 1). The CA3
egion of the hippocampus showed decreased thickness
f the pyramidal layer and severely damaged apoptotic
eurocytes in the form of pyknotic, shrunken, vacuolated
eurons with hyperchromatic nuclei, and dilated hemor-
hagic blood vessels (Figure 4).
In the cerebral cortex sections stained for anti-Bcl2,
ome neurocytes showed a weak perinuclear membrane
eaction, and a small number of normal neurocytes
howed a strong positive reaction (Figure 2). In anti-
53-stained sections, apoptotic neurocytes had a strong
ositive nuclear reaction, while a small number of nor-
al  neurocytes showed a negative reaction (Figure 3). In
he CA3 region of the hippocampus stained for anti-Bcl-2,
 large number of apoptotic neurocytes showed negative
erinuclear membrane immunoreactivity, while a small
umber of neurocytes showed a positive perinuclear mem-
rane immune reaction (Figure 5). Immunohistochemical
taining of the CA3 region with anti-p53 showed pos-
tive nuclear immunoreactivity of apoptotic neurocytes
Figures 6, 19 and 20; Table 1).
.2. Triptorelin treated rats (Group III)Light microscopic examination of the cerebral cortex of
riptorelin-treated rats showed healthy neurocytes similar
o the control group, with central large vesicular nuclei thatanti-Bcl2 staining; magniﬁcation: 400×.
contained one or more nucleoli and peripheral distribution
of Nissl granules (Figure 7). Light microscopic examination
of the hippocampus in the CA3 region showed the thickness
of the pyramidal layer and most of the neurocytes appeared
normal as the control group (Figure 10). In sections
stained for anti-Bcl2, most of the cerebral cortical neuro-
cytes showed positive immunoreactivity in the perinuclear
membranes (Figure 8). Most of the nuclei of the cerebral
cortical neurocytes showed negative immunoreactivity for
anti-p53 (Figure 9). The CA3 region of the hippocampus
stained with anti-Bcl2 showed positive immunoreactivity
in the perinuclear membrane in most of the neurocytes
(Figure 11) but showed negative immunohistochemicalFigure 3. Photomicrograph of anti-p53-stained section of the cerebral
cortex of a cyclophosphamide-treated rat (Group II) showing brown
positively immunoreactive neurocyte nuclei, with marked expression of
positively immunoreactive apoptotic cells (arrows). Stain: immunohisto-
chemical anti-p53 staining; magniﬁcation: 400×.
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Figure 4. Photomicrograph of hippocampus of a cyclophosphamide-
treated rat (Group II) showing decreased thickness of pyramidal cell layer
in  the CA3 region, with increased apoptotic neurons with dystrophic
changes in the form of shrunken hyperchromatic, irregular with chro-
Figure 5. Photomicrograph of an anti-Bcl2-stained section of the hip-
pocampus of a cyclophosphamide-treated rat (Group II) showing brownmatolysis and abnormal Nissl granule distribution (arrows) with dilated
blood vessel (*), and degenerated and vacuolated neurocytes (arrow head).
Stain: hematoxylin and eosin; magniﬁcation 400×.
3.3. Rats treated with cyclophosphamide and triptorelin
(Group IV)
Light microscopic examination of the cerebral cortex of
rats treated with CP and triptorelin showed considerable
Table 1
Changes in the independent sample t test and probability (p) of the apoptotic inde
in  the control and experimental groups.
Cerebral cortex
IHC Groups for comparison
Anti-P53 Group I (mean ± SD) 1.5 ± 0.9
Group II (mean ± SD) 20.8 ± 5.3
Group III (mean ± SD) 2.1 ± 0.4 
Group IV (mean ± SD) 14.6 ± 6.2
Anti-Bcl2 Group I (mean ± SD) 28.6 ± 8.4
Group II (mean ± SD) 28.6 ± 8.4
Group III (mean ± SD) 24.5 ± 3.4 
Group IV (mean ± SD) 18.2 ± 9.4
Hippocampus
IHC Groups for comparison 
Anti-P53 Group I (mean ± SD) 0.3 ± 0.2
Group II (mean ± SD) 25.6 ± 8.3
Group III (mean ± SD) 0.5 ± 0.1
Group IV (mean ± SD) 12.3 ± 7.2
Anti-Bcl2 Group I (mean ± SD) 34.9 ± 7.8
Group II (mean ± SD) 10.5 ± 4.6
Group III (mean ± SD) 29.4 ± 5.1 
Group IV (mean ± SD) 20.9 ± 6.3
IHC = immunohistochemistry; SD = standard deviation.immunoreactive staining of perinuclear membranes of neurocytes. There
was  less positive immunoreactivity in some apoptotic cells (arrows).
Stain: immunohistochemical anti-Bcl2 staining; magniﬁcation: 400×.
improvement in neurocytes, and most of them appeared
normal with large vesicular nuclei containing one or more
nucleoli and peripheral distribution of Nissl granules.
A small number of neurocytes still showed dystrophic
changes in the form of hyperchromatic nuclei with
abnormal Nissl granule distribution and vacuolation
(Figure 13). Light microscopic examination of the CA3
x of neurocytes of the cerebral cortex and the hippocampus of adult rats
t p
Group II 11.35 <0.001***
Group III 1.93 0.069
Group IV 6.6 <0.001***
Group III 11.13 <0.001***
Group IV 2.4 0.027*
Group IV 6.36 <0.001***
Group II 7.44 <0.001***
Group III 1.43 0.17
Group IV 2.64 0.016*
Group III 12.26 <0.001***
Group IV 3.41 0.003**
Group IV 1.99 0.061
t p
Group II 9.64 <0.001***
Group III 16.97 0.09
Group IV 5.27 <0.001***
Group III 9.18 <0.001***
Group IV 3.83 0.0012**
Group IV 4.74 <0.001***
Group II 8.52 <0.001***
Group III 1.87 0.78
Group IV 4.42 <0.001***
Group III 8.7 <0.001***
Group IV 4.22 <0.001***
Group IV 3.32 0.003**
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Figure 6. Photomicrograph of an anti-p53-stained section of the hip-
pocampus of a cyclophosphamide-treated rat (Group II) showing brown
immunoreactive staining of neurocyte nuclei, with marked expression of
apoptotic cells (arrows). Stain: immunohistochemical anti-p53 staining;
magniﬁcation: 400×.
Figure 7. Photomicrograph of cerebral cortex of a triptorelin-treated rat
(group III) showing near normal neurons, with central large vesicular
nuclei, containing one or more nucleoli, and peripheral distribution of
Nissl granules (arrows). Stain: hematoxylin and eosin; magniﬁcation:
400×.
Figure 8. Photomicrograph of an anti-Bcl2-stained section of the cerebral
cortex of a triptorelin-treated rat (Group III) showing positive immunore-
activity of neurons in the form of brown staining of neurocyte perinuclear
membranes (arrows). Stain: immunohistochemical anti-Bcl2 staining;
magniﬁcation: 400×.
Figure 9. Photomicrograph of an anti-p53-stained section of the cerebral
cortex of a triptorelin-treated rat (Group III) showing negative immunore-
activity of neurons in the form of brown staining of cerebral cortex
neurocyte nuclei (arrows). Stain: immunohistochemical anti-p53 stain-
ing; magniﬁcation: 400×.
Figure 10. Photomicrograph of hippocampus of a triptorelin-treated rat
(Group III) showing near normal thickness of the pyramidal cell layer of
the CA3 region, with normal neurons (arrows). Stain: hematoxylin and
eosin; magniﬁcation: 400×.
Figure 11. Photomicrograph of an anti-Bcl2-stained section of the hip-
pocampus of a triptorelin-treated rat (Group III) showing positive
immunoreactivity of neurocyte perinuclear membranes (arrows) Stain:
immunohistochemical anti-Bcl2 staining; magniﬁcation: 400×.
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Figure 12. Photomicrograph of an anti-p53-stained section of hip- Figure 14. Photomicrograph of an anti-Bcl2-stained section of the cere-
bral cortex of a cyclophosphamide-treated rat receiving triptorelin (Group
IV) showing positive immunoreactivity of most of the neurocyte peri-pocampus of triptorelin-treated rats (Group III) showing negative
immunoreactivity in neurocyte nuclei (arrows) Stain: immunohistochem-
ical anti-p53 staining; magniﬁcation: 400×.
region of the hippocampus showed a thick pyramidal
layer of near normal appearance, and obvious improve-
ment in most of the neurocytes, which showed normal
central vesicular nucleoli with normal distribution of
Nissl granules. Some neurocytes showed apoptotic ﬁgures
(Figure 16). Immunohistochemically stained sections of
cerebral cortex showed a large number of neurocytes with
positive perinuclear membrane immunoreactivity for
anti-Bcl2, while a small number of apoptotic neurocytes
showed negative immunoreactivity (Figure 14). Most
neurocytes showed negative immunoreactivity with
anti-p53 staining (Figure 15). Immunohistochemically
stained sections of the CA3 region of the hippocampus
showed variation in immunoreactivity for Bcl2, Most of
the neurocytes showed positive immunoreactivity while
a small number of neurons showed apoptotic changes
with negative immunoreactivity (Figure 17). In anti-p53
Figure 13. Photomicrograph of cerebral cortex of a cyclophosphamide-
treated rat receiving triptorelin (Group IV) showing near normal neurons
with central large vesicular nuclei, containing one or more nucleoli, and
peripheral distribution of Nissl granules (arrows head), and small number
of  neurons with dystrophic changes in the form of shrunken hyperchro-
matic, irregular (arrows), and abnormal Nissl granules distribution. Stain:
hematoxylin and eosin; magniﬁcation: 400×.nuclear membranes neurons (arrows), with a small number of apoptotic
neurons with negative immunoreactivity (arrow head). Stain: immuno-
histochemical anti-Bcl2 staining; magniﬁcation: 400×.
stained sections, nearly all neurocytes showed negative
nuclear immunoreactivity (Figures 18–20; Table 1).
4. Discussion
The number of cancer survivors has increased in the
last three decades due to highly efﬁcient chemotherapy
regimens. However, 60–75% of cancer survivors face at
least one serious side effect of chemotherapy [1]. In this
study, we investigated the effect of CP alone and with the
protective effect of triptorelin on the cerebral cortex and
hippocampus of male albino rats.
Group II showed dilated blood vessels (Figures 1 and 4),
this result was conﬁrmed by adjuvant chemotherapy for
breast cancer that has been related to transient ischemic
attacks and stroke with brain infarctions and cerebral
microbleeds. These vascular lesions are indicative of
Figure 15. Photomicrograph of an anti-p53-stained section of the cere-
bral cortex of a cyclophosphamide-treated rat receiving triptorelin (Group
IV) showing negative immunoreactivity in the nuclei of the neurons
(arrows). Stain: immunohistochemical anti-p53 staining; magniﬁcation:
400×.
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Figure 16. Photomicrograph of the hippocampus of a cyclophosphamide-
treated rat receiving triptorelin (Group IV) showing normal neurons n the
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Figure 18. Photomicrograph of an anti-p53-stained section of the hip-
pocampus of a cyclophosphamide-treated rat receiving triptorelin (Groupyramidal cell layer of the CA3 region (arrows), with a small number of
poptotic neurons (arrow head). Stain: hematoxylin and eosin; magniﬁ-
ation: 400×.
erebrovascular impairment that could partially explain
he association between chemotherapy and cognitive dys-
unction [34]. Histopathological study of the same group of
ats revealed that the CP induced highly signiﬁcant dys-
rophic and apoptotic changes in the neurocytes of the
erebral cortex and hippocampus (Figures 1, 4, 19 and 20;
able 1). In contrast, other studies reported that the hema-
oxylin and eosin staining did not reveal any unusual hip-
ocampal structure in adult mice 10 days after CP injection.
his suggests that acute injection of 40 mg/kg CP does not
nduce neural apoptosis in the hippocampus of adult mice.
The histopathological results were conﬁrmed by
mmunohistochemical studies that showed a large number
f apoptotic neurons with a positive reaction for p53 and
ess positive reaction for Bcl2 (Figures 2, 3, 5, 6, 19 and 20;
able 1). This result was in line with an experimental
tudy that had used immunohistochemical markers Ki-67
igure 17. Photomicrograph of an anti-Bcl2-stained section of a
yclophosphamide-treated rat receiving triptorelin (Group IV) showing
rown staining of hippocampal neurocyte perinuclear membranes. Posi-
ive immunoreactivity of most neurons (arrows), with a small number of
poptotic neurons with negative immunoreactivity (arrow head). Stain:
mmunohistochemical anti-Bcl2 staining; magniﬁcation: 400×.IV)  showing brown staining of neurocyte nuclei, indicating positive
immunoreactivity (arrows). Stain: immunohistochemical anti-p53 stain-
ing,; magniﬁcation: 400×.
(a proliferating cell marker) and DCX (an immature neu-
ronal cell marker) for neurogenesis in hippocampus [35].
This work had studied the acute effect of intraperitoneal
injection of CP. It showed a signiﬁcant decrease in the
number of Ki-67- and DCX-positive cells at 12 hours after
injection of CP, reaching the lowest level at 24 hours after
injection. This suggests that CP interrupts hippocampal
functions through suppression of neurogenesis. However,
during the period from 12 hours to 4 days after injection, CP
transiently decreased the number of cells positive for Ki-67
and DCX in the dentate gyrus of adult hippocampi, indicat-
ing that CP transiently inhibits adult hippocampal neuroge-
nesis. This suggests that CP only suppresses the generation
of new neural cells, possibly by transient arrest of the cell
cycle, in the dentate gyrus of the adult hippocampus.
In another study, CP did not induce apoptosis in the
adult dentate gyrus, in contrast to induction by irradiation
[36].
Computed tomography neuroimaging in patients with
breast cancer showed decreased density of gray mat-
ter in the cerebral cortex 1 month after completion
of chemotherapy, particularly in frontal regions [37].
Chemotherapeutic agents caused increased cell death and
decreased cell division in the dentate gyrus of the hip-
pocampus and the corpus callosum in mice [5].
The results of this work revealed the effect of triptore-
lin on the cerebral cortex and hippocampus (group III).
The results showed no signiﬁcant difference in compar-
ison to that of the control group, in the form of normal
neurons in cerebral cortex and hippocampus, with normal
thickness of the pyramidal cell layer of CA3 (Figures. 7,
10, 19 and 20; Table 1 These results were in association
with the anti-Bcl2 stained section of the cerebral cortex
and hippocampus, which showed positive immunoreactiv-
ity of neurons (Figures 8 and 11), and the anti-p53 stained
section, which revealed negative immunoreactivity of neu-
rocytes nuclei (Figures 9 and 12).
The histopathological study of Group IV showed normal
neurons but a small number of neurons with dystrophic
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ral corteFigure 19. Changes in the apoptotic index of the neurocytes of the cereb
experimental groups.
changes in the neurocytes of cerebral cortex (Figure 13).
The CA3 region of the hippocampus of the same group
showed a normal pyramidal cell layer and a small num-
ber of apoptotic neurons (Figure 16). Anti-Bcl2-stained
sections of cerebral cortex and hippocampus showed
normal positive immunoreactivity in most of the neuro-
cytes, with a small number of negative apoptotic neurons
(Figures 14 and 17). However, in the anti-p53-stained
sections, the cerebral cortex and hippocampus showed
negative immunoreactivity in the nuclei of the neurons
(Figures 15 and 18). These results were conﬁrmed by mild
to moderately signiﬁcant changes in the AI of the cere-
bral cortex in comparison to highly signiﬁcant changes
in the AI of the hippocampus, which indicates the sen-
sitivity of the hippocampal cells (Figures 19 and 20;
Table 1).x with (A) anti-p53 (B) anti-Bcl2 staining in adult rats in the control and
Immunoreactive GnRH type I receptors in mouse and
sheep brains show that staining is restricted to the
pyramidal cell layer in the cerebral cortex and hippocam-
pus [24]. Other studies have indicated high densities of
GnRH receptors in several regions of the brain including
the CA1 and CA3 regions of the hippocampus [38]. Activa-
tion of GnRH agonists produces long-lasting enhancement
of synaptic transmission mediated by ionotropic glutamate
receptors in the CA1 pyramidal neurons of the rat hip-
pocampus [39]. GnRH alters the electrical properties of
rat hippocampal pyramidal cells and stimulates increased
inositol-1,4,5-trisphosphate production within these cells
[39,40]. In the rat and sheep’s hippocampal and den-
tate gyrus GnRHR-expressing neurons co-express estrogen
receptor . Estrogen receptor  is a potent tumor suppres-
sor and plays a crucial role in many cancer types such as
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iigure 20. Changes in the apoptotic index of the neurocytes of the hippo
xperimental groups.
rostate cancer [41]. GnRH constitutes an integral compo-
ent of the neurodegenerative pathology that accompanies
lzheimer’s disease [42].
Other histopathological studies on the dentate gyrus
nd hippocampus in CP-treated show that Decapeptyl has a
upporting effect on hippocampal neuronal (hippocampus
rea neurons) damage in animals that received chemother-
peutic agents [23].
In conclusion, our study shows that triptorelin can
everse the apoptotic changes induced by CP therapy,
hich is more signiﬁcant in the hippocampus than in the
erebral cortex.onﬂict of interest
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